Your browser doesn't support javascript.
Clinical approach to the inflammatory etiology of cardiovascular diseases.
Ruscica, Massimiliano; Corsini, Alberto; Ferri, Nicola; Banach, Maciej; Sirtori, Cesare R.
  • Ruscica M; Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
  • Corsini A; Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy; Multimedica IRCCS, Milano, Italy.
  • Ferri N; Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua, Italy.
  • Banach M; Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Electronic address: maciej.banach@iclo
  • Sirtori CR; Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
Pharmacol Res ; 159: 104916, 2020 09.
Article in English | MEDLINE | ID: covidwho-324253
ABSTRACT
Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of cholesterol itself and from well-established molecular mechanisms. Raised progenitor cell recruitment after major events and clonal hematopoiesis related mechanisms have provided an improved understanding of factors regulating inflammatory phenomena. Trials with inflammation antagonists have led to an extensive evaluation of biomarkers such as the high sensitivity C reactive protein (hsCRP), not exerting a causative role, but frequently indicative of the individual cardiovascular (CV) risk. Aim of this review is to provide indication on the anti-inflammatory profile of agents of general use in CV prevention, i.e. affecting lipids, blood pressure, diabetes as well nutraceuticals such as n-3 fatty acids. A crucial issue in the evaluation of the benefit of the anti-inflammatory activity is the frequent discordance between a beneficial activity on a major risk factor and associated changes of hsCRP, as in the case of statins vs PCSK9 antagonists. In hypertension, angiotensin converting enzyme inhibitors exert an optimal anti-inflammatory activity, vs the case of sartans. The remarkable preventive activity of SLGT-2 inhibitors in heart failure is not associated with a clear anti-inflammatory mechanism. Finally, icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27 % reduction of hsCRP. The inflammation-based approach to arterial disease has considerably gained from an improved understanding of the clinical diagnostic strategy and from a better knowledge on the mode of action of numerous agents, including nutraceuticals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Agents / Cardiovascular Diseases / Cardiovascular System / Inflammation Mediators / Inflammation / Anti-Inflammatory Agents Type of study: Etiology study / Experimental Studies / Observational study / Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Pharmacol Res Journal subject: Pharmacology Year: 2020 Document Type: Article Affiliation country: J.phrs.2020.104916

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Agents / Cardiovascular Diseases / Cardiovascular System / Inflammation Mediators / Inflammation / Anti-Inflammatory Agents Type of study: Etiology study / Experimental Studies / Observational study / Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Pharmacol Res Journal subject: Pharmacology Year: 2020 Document Type: Article Affiliation country: J.phrs.2020.104916